|Bid||167.58 x 3100|
|Ask||185.04 x 800|
|Day's Range||180.11 - 183.46|
|52 Week Range||119.29 - 184.83|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||174.78|
CAMBRIDGE, Mass., July 21, 2021--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open.
A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]